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An extended mini-complement factor H molecule
ameliorates experimental C3 glomerulopathy
Eva-Maria Nichols1,3, Thomas D. Barbour2,3, Isabel Y. Pappworth1, Edwin K.S. Wong1, Jeremy M. Palmer1,
Neil S. Sheerin1, Matthew C. Pickering2 and Kevin J. Marchbank1
1Institutes of Cellular and Genetic Medicine, School of Medicine, Newcastle University, Newcastle upon Tyne, UK and 2Centre for
Complement and Inflammation Research, Imperial College London, London, UK
Abnormal regulation of the complement alternative pathway
is associated with C3 glomerulopathy. Complement factor H
is the main plasma regulator of the alternative pathway
and consists of 20 short consensus repeat (SCR) domains.
Although recombinant full-length factor H represents a
logical treatment for C3 glomerulopathy, its production
has proved challenging. We and others have designed
recombinant mini-factor H proteins in which ‘non-essential’
SCR domains have been removed. Here, we report the in vitro
and in vivo effects of a mini-complement factor H protein,
FH1–5^18–20, using the unique factor H–deficient (Cfh− /− )
mouse model of C3 glomerulopathy. FH1–5^18–20 is comprised
of the key complement regulatory domains (SCRs 1–5) linked
to the surface recognition domains (SCRs 18–20).
Intraperitoneal injection of FH1–5^18–20 in Cfh− /− mice
reduced abnormal glomerular C3 deposition, similar to
full-length factor H. Systemic effects on plasma alternative
pathway control were comparatively modest, in association
with a short half-life. Thus, FH1–5^18–20 is a potential
therapeutic agent for C3 glomerulopathy and other renal
conditions with alternative pathway-mediated tissue injury.
Kidney International advance online publication, 29 July 2015;
doi:10.1038/ki.2015.233
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Factor H (FH, 150 kDa) is the key regulator of complement
activation in plasma.1,2 FH inhibits the C3b amplification
loop by preventing formation and promoting dissociation of
the alternative pathway (AP) C3 convertase, and by acting
as a cofactor for factor I (FI)–mediated C3b cleavage.1,3
It comprises 20 short consensus repeat (SCR) domains, with
amino (N)-terminal SCRs 1–4 accounting for its AP
regulatory functions. FH is targeted to specific tissues via
two binding domains that recognize different heparan sulfate
species.4 The principle binding site for heparan sulfate species
of the retina is located in SCR 7, whereas SCRs 19–20 target
glomerular heparan sulfate.5 Indeed, C-terminal SCRs 19–20
are critical for interaction with tissue-bound C3b and cell
surface polyanions, enabling FH to regulate the AP on host
cell surfaces.2,6 Uncontrolled C3 activation via the AP because
of deficiency or dysfunction of FH is associated with the
development of C3 glomerulopathy (C3G).7 The pathological
hallmark of C3G is predominant C3 accumulation within the
glomerulus, leading to end-stage kidney disease within 10
years of diagnosis in ~ 40% of patients.8 Currently, there is no
proven treatment for C3G, although a small prospective trial
and several case reports suggest that the C5 inhibitor
eculizumab may be beneficial in some patients.9–11
Mice with targeted homozygous deficiency of murine FH
(Cfh− /− ) demonstrate low plasma C3 levels and a linear
pattern of C3 staining in the glomerulus, and eventually
develop membranoproliferative glomerulonephritis.12 Murine
experimental C3G thus provides a useful model for studying
the pathogenetic mechanisms and response to novel ther-
apeutics of C3G. Injection of human FH or murine Cfh has
been shown to restore plasma C3 levels and reduce
glomerular C3 deposition in Cfh− /− mice at 24 h.13,14
Accordingly, recombinant FH has been proposed as a logical
treatment for establishing physiological AP control and
halting disease progression in patients with C3G. However,
because of the size and complexity of the FH protein,
production of therapeutic quantities represents a significant
challenge.15–17 Here, we describe the generation and success-
ful administration in Cfh− /− mice of a mini-FH protein
(FH1–5^18–20), which is comprised of the key functional
domains of FH. FH1–5^18–20 reduced glomerular C3 reactivity
similar to full-length FH while also partially restoring plasma
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C3 levels. These data indicate a plausible therapeutic role for
FH1–5^18–20 in patients with C3G and other disorders of
complement regulation.
RESULTS
Generation of FH1–5 and the Newcastle mini-FH (FH1–5^18–20)
proteins
For our mini-FH construct, we included the first five SCRs of
the N-terminal region of FH, as we and others have found
that SCRs 1–5 of FH has improved function over SCRs 1–4
(Supplementary Figure S1 online; Huang et al.,18 Cheng
et al.,19 and Gordon et al.20); SCR 5 is also the target of
monoclonal antibody OX-24,21 allowing an additional means
to purify/identify the construct. We included SCR 18 at the C
terminus to provide spacing to the construct and included a
hexa-histidine tag as the primary means of purification, as
well as providing additional flexibility/spacing between
SCRs 5 and 18. FH1–5^18–20 and FH1–5 were expressed in
Chinese hamster ovary cells and yielded 2 and 4 mg/l, respec-
tively. After two-step purification, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis confirmed the purity of
both FH1–5 and FH1–5^18–20, and that they migrated at their
predicted molecular weight of ~ 36 and 59 kDa, respectively
(Figure 1a). To assess the binding of FH1–5^18–20 to key
ligands, microtiter plates were coated with C3b or heparin
(a model polyanion) and binding of equimolar amounts of
FH, FH1–5, and FH1–5^18–20 measured. All three FH proteins
bound to C3b, whereas only FH and FH1–5^18–20 bound
heparin as detected by a polyclonal anti-FH (Figure 1b and c).
FH and FH1–5^18–20 bound to C3b or heparin in an equivalent
manner and could be inhibited by specific monoclonal
antibody, confirming the specificity of the interaction in this
assay. In light of recent findings regarding deregulation of FH
function by the FHR proteins22 and to establish if FH1–5^18–20
was also susceptible to deregulation, we carried out a C3b-
binding/competition assay using equimolar amounts of FH,
FH1–5, and FH1–5^18–20 and increasing doses of recombinant
FHR1 or FHR5. In this assay, FH1–5^18–20 was significantly
more resistant to deregulation compared with FH at all
concentrations of FHR (Figure 1d and e) but was still
deregulated at the highest FHR doses (1.8 and 0.6μmol/l,
respectively).
Fluid-phase regulatory capacity of recombinant FH1–5^18–20 is
comparable to serum-derived FH
FI requires a cofactor such as FH to mediate cleavage of the
C3b α-chain. The ability of FH1–5^18–20 to serve as a cofactor
for FI was initially tested in a standard fluid-phase cofactor
assay23 and then in an SRBC (sheep red blood cells) assay.24
C3b, FI, and a cofactor (FH, FH1–5, or FH1–5^18–20) were
incubated at varying equimolar concentrations. Encoura-
gingly, FH1–5^18–20 performed significantly better than FH1–5
and was consistently more potent than serum-derived FH in
the protection of C3b-coated SRBCs from lysis in this assay
(Figure 2a). However, while comparable to FH, FH1–5^18–20
was not superior in the classical fluid-phase assays
(Supplementary Figure S2 online). We also measured the
decay-accelerating activity of FH and the recombinant
constructs using C3b-coated SRBCs; again, FH and
FH1–5^18–20 demonstrated 10-fold greater ability to decay
the C3b convertase on SRBCs compared with FH1–5.
However, in this assay FH1–5^18–20 decay-accelerating activity
function was indistinguishable from that of FH (Figure 2b).
Overall, these data suggest that FH1–5^18–20 has maintained
the complement regulatory function of FH.
FH1–5^18–20 is highly efficient in protecting SRBCs from
complement attack by aHUS patient or FH functionally
depleted serum
SRBCs are normally resistant to AP-driven complement
attack because FH readily binds to their surface via its C
terminus. This fact has been exploited by Sanchez-Corral
et al.25 who demonstrated that serum from patients with
mutations in FH that affected the C terminus would readily
lyse SRBCs. We have previously used this assay to confirm a
defect in complement regulation in a patient with an FH
hybrid gene.26 Addition of FH or FH1–5^18–20 to serum from
an aHUS (atypical hemolytic uremic syndrome) patient with
C-terminus mutation was highly effective in blocking SRBC
lysis (Figure 3b), confirming that increasing FH levels is
sufficient to reverse an inherent regulatory defect in patient
serum, with FH1–5^18–20 being equivalent to an equimolar
concentration of FH. Using OX-24 to block FH function in
the normal serum, which prevents FH binding to C3b on the
erythrocyte surface,27 we were able to show that functional
loss of FH regulatory function by antibody blockade of the N
terminus of FH can also be reversed by the addition of FH or
FH1–5^18–20 (Figure 3c). The data indicate, in these cell-based
assays, that FH1–5^18–20 is marginally more effective compared
with FH in complement regulatory function in patient serum
and may be useful for treatment of patients with either
defective FH or antibodies that block FH function.
FH1–5^18–20 reduces glomerular C3 staining in Cfh− /− mice at
doses that incompletely restore plasma C3 levels
We assessed the ability of FH1–5^18–20 to influence plasma and
glomerular C3 in vivo by administering the protein to
Cfh− /− mice (Figure 4a). After a single intraperitoneal 12
nmol dose of either FH1–5^18–20 or FH1–5, plasma C3 levels
significantly increased at 2 and 6 h after injection reaching
~ 20% of wild-type levels at 6 h (Figure 4a). Both injected
proteins were detectable in plasma at 2 h after injection but
absent or barely detectable at the 6 h time point (Figure 4b).
In contrast, after a single injection of 3 nmol of serum-derived
FH (the dose used successfully by Fakhouri et al.14), the
injected FH was detectable at comparable concentrations 2
and 6 h after injection, and plasma C3 increased to ~ 60% of
wild-type levels at the 6 h time point (Figure 4a and b).
Glomerular C3 immunostaining fluorescent intensity was
significantly reduced 6 h after injection of FH1–5^18–20 to a
comparable degree to that seen following FH (Figure 4c). No
significant reduction in glomerular C3 staining was seen in
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the group that received a single injection of the FH1–5 protein
(Figure 4c). We were able to detect both FH and FH1–5^18–20,
but not FH1–5 protein, in the glomerulus using the OX-24
antibody (Figure 4d). We next injected FH1–5^18–20 at 6-
hourly intervals over a 24 h period at which time point we
assessed glomerular C3 staining. Similar to our findings 6 h
after injection of the FH1–5^18–20 protein, glomerular C3
staining intensity was significantly reduced 24 h following
multiple injections, but in these animals we also noted areas
of mesangial staining, comparable to that seen previously 24 h
following injection of full-length FH (Fakhouri et al.14;
Supplementary Figure S3A and B online). No change in
glomerular C3d reactivity was detectable (Supplementary
Figure S3B).
DISCUSSION
Given the robust association of FH deficiency/dysfunction
with severe, progressive renal disease, therapeutic evaluation
of full-length recombinant FH has long seemed merited.
However, this has not been possible. FH is a large
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Figure 1 | Initial analysis of recombinant FH1–5 and FH1–5^18–20 protein. (a) Serum-purified full-length factor H (FH) or Chinese hamster ovary
(CHO) cells expressed and purified recombinant FH1–5 and FH1–5^18–20 were visualized on 12.5% sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) using Coomassie staining. Proteins are represented schematically next to bands and molecular weight (MW) markers are indicated. Basic
functional properties of the new construct were determined in enzyme-linked immunosorbent assay (ELISA) assays. To detect binding of FH1–5
and FH1–5^18–20 to (b) C3b and (c) heparin, FH proteins (10 nmol/l) were applied to appropriately coated ELISA plates. Preincubation of samples
with monoclonal antibodies OX-24 and L20/3 or L20/3 (at 1.5 molar equivalence to FH) was carried out as indicated. Serum-purified FH acted as
a positive control. No significant change was noted between FH1–5^18–20 and FH binding to C3b or heparin using two-way analysis of variance
(ANOVA) with Bonferroni multiple comparisons test. Binding of FH proteins was detected using a goat anti-human FH polyserum, followed by a
horse radish peroxidase (HRP)–conjugated donkey anti-goat Ig secondary antibody. The ability of (d) rFHR1 and (e) rFHR5 protein to interfere
with FH1–5 and FH1–5^18–20 binding to a heavily C3b-coated surface is shown. Data shown are a composite of three similar experiments,
mean± s.e.m. is shown. Two-way ANOVA with Bonferroni multiple comparisons test confirms that FH1–5 and FH1–5^18–20 bind significantly worse
or significantly better, respectively, compared with FH to C3b in the presence of FHRs. CFA, cofactor activity; DAA, decay-accelerating activity;
NS, nonsignificant.
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glycoprotein with eight confirmed N-glycosylation sites and
40 disulfide bonds,28 making large-scale manufacture techni-
cally difficult. Even if production issues can be addressed,29
recombinant FH will lack the normal mammalian glycosyla-
tion pattern, predisposing it to rapid clearance by natural
antibody/innate immune recognition.30 By contrast, produc-
tion of recombinant mini-FH proteins is technically feasible
and has the added theoretical advantage of circumventing
immune evasion by strains of Neisseria meningitides.31 The
latter are able to hijack FH by binding of SCR 6 through the
meningococcal cell surface protein, FH-binding protein.32,33
Here, we show for the first time that a mini-FH protein,
FH1–5^18–20, is able to regulate the AP in vivo, effectively
reversing glomerular C3 accumulation and transiently
increasing plasma C3 levels in Cfh− /− mice.
Administered as a single 12 nmol injection, FH1–5^18–20 had
a significant effect on plasma C3 levels between 2 and 6 h, and
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Figure 2 | FH1–5^18–20 cell membrane complement regulatory
activity comparable to factor H (FH). (a) FI (or Factor I) cofactor
activity: C3b-coated sheep erythrocytes were exposed to 2.5 μg/ml
factor I (FI) and either FH (0.8–100 nmol/l), FH1–5^18–20 (0.8–100 nmol/
l), or FH1–5 (6–750 nmol/l) and incubated at 25 °C inactivate the C3b.
Remaining C3b was induced to create C3 convertase whose level was
then determined by the amount of lysis of red cells after incubation
with FB- and FH-depleted serum in phosphate-buffered saline (PBS)/
20 mmol/l ethylenediaminetetraacetic acid (EDTA). (b) Decay-
accelerating function of FH1–5^18–20 was assayed using sheep
erythrocytes precoated with AP convertase (see Materials and
Methods). Data shown are mean± s.e.m. of at least six independent
titrations and a composite of two independent experiments (cofactor
activity (CFA)) and four independent experiments (decay-accelerating
activity). FH1–5^18–20 has significantly improved CFA function
compared with FH using two-way analysis of variance (ANOVA) with
Bonferroni multiple comparisons test, **P40.001.
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Figure 3 | FH1–5^18–20 protects sheep red blood cells (SRBCs) from
lysis by atypical hemolytic uremic syndrome (aHUS) patient sera.
(a) Serum from an aHUS patient known to carry a heterozygous CFH/
CFHR1 (complement factor H/CFHR1) hybrid gene lyses SRBCs in a
dose-dependent manner, whereas serum from a normal individual
does not. Increasing the quantity of OX-24 monoclonal antibody
(mAb) added to 20 μl normal serum blocks factor H (FH) function in a
dose-dependent manner. Volume of serum or OX-24 Ab added is
indicated on the X axis. (b) aHUS patient serum (12.5 μl) was spiked
with increasing concentration of FH reagents as indicated and
prevented lysis of red cells. (c) Normal patient serum was mixed with
OX-24 (15 μg/20 μl serum) before the addition of increasing
concentration of FH/reagent as indicated. SRBC lysis with serum but
no FH reagent was adjusted to represent 100% lysis. Data shown are
mean± s.e.m. of six independent titrations and a composite of two
independent experiments. FH1–5^18–20 has significantly improved
function compared with FH by two-way analysis of variance (ANOVA),
with Bonferroni multiple comparisons test. *P40.05 and **P40.001.
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produced an equivalent reduction in glomerular C3 reactivity
to full-length FH (Figure 4a). As expected because of the short
time (6 h) after infusion of FH or FH1–5^18–20, no evidence of
glomerular immunoglobulin G (IgG) deposition was detected
(data not shown). A novel finding is that this effect on
glomerular C3 staining was associated with detection of
administered FH or FH1–5^18–20 in a linear staining pattern
within the glomerulus. This could indicate the therapeutic
targeting of FH1–5^18–20 to the site of pathological C3 turnover
within the kidney, which would be as expected as SCRs 19–20
are known to target glomerular heparan sulfate.5 Thus, in
kidney pathologies that are mediated through deficiency or
functional deficits of FH, supplementation with FH1–5^18–20 is
expected to be therapeutic. By contrast, FH1–5^18–20 would be
less beneficial in retinal pathology (because of the absence of
targeting provided in SCRs 6–8; Langford-Smith et al.4 and
Clark et al.5), although this remains to be formally tested. An
equivalent total 12 nmol dose, delivered in 6-hourly 3 nmol
increments, also reduced glomerular C3 reactivity at the 24 h
end point (Supplementary Figure S3 online). The results
demonstrate that FH1–5^18–20, unlike FH1–5, engages the same
therapeutic mechanism as FH and is thus suited for
replacement therapy. However, in the absence of detailed
in vivo dose–response experiments, the present study does not
allow a definitive conclusion on the relative efficacies of FH1–5,
FH1–5^18–20, and FH. In vitro, FH1–5^18–20 demonstrated
comparable or improved function to that of FH in the red
cell-based assays (Figures 2 and 3). An ability to protect cells
from complement attack by aHUS patient sera or serum spiked
with FH function-blocking antibody (Figure 3b and c) by
FH1–5^18–20 suggests the therapeutic potential in the clinical
setting of aHUS and in patients who present with anti-FH
autoantibodies. However, the successful treatment of autoanti-
body positive patients with FH1–5^18–20 may depend on the
amount of ‘free’ autoantibody and the target site of the
autoantibody. Encouragingly, recent data suggests that anti-FH
autoantibodies associated with C3G are of lower affinity, don’t
readily form immune complexes and don’t generally disturb
the interaction of FH with C3b,34 suggesting FH1–5^18–20 could
be effective in C3G where anti-FH autoantibodies are present.
Furthermore, the ability of FH1–5^18–20 to resist deregulation by
FHR1 and FHR5 may also be an advantage in subtypes of C3G
where the putative pathogenic mechanism is FH deregulation
by abnormal FHR proteins, although we have not directly
tested that herein. By contrast, the fluid-phase (Supplementary
Figure S2 online) and enzyme-linked immunosorbent assay
(ELISA)-based assays (Figure 1b) used suggest a potential
reduced efficacy of FH1–5^18–20 to interact with C3b compared
with FH under certain circumstances. Ongoing studies
comparing our mini-FH construct to the previously reported
versions35,36 (and TT30, that is, CR2 SCRs 1 to 4–FH SCRs 1 to
5), in dose–response studies on human erythrocytes, aim to
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Figure 4 | Effect of FH1–5^18–20 on plasma C3 levels and glomerular C3 staining in Cfh− /− mice. (a) Plasma C3 levels increased significantly
2 and 6 h after injection of 3 nmol full-length factor H (FH) or 12 nmol FH1–5^18–20 compared with phosphate-buffered saline (PBS). (b) FH
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address these apparent disparities; these are likely because of
subtle (or inherent) differences in targeting preferences of these
constructs, giving each construct an advantage for a particular
surface.
FH1–5^18–20 is the largest of the mini-FH constructs
generated to date,35,36 comprising SCRs 1–5, a short internal
hexa-histidine tag linker, and SCRs 18–20. We also chose to
use mammalian expression systems to minimize any glyco-
sylation differences that may arise in the production of
FH1–5^18–20 and reduce potential problems associated with
immune clearance that may limit the use of the Pichia-29,36 or
Baculovirus-35 produced FH recombinant proteins.30 It was
therefore surprising that serum half-life was apparently so
short (Figure 4b), although that said, it is similar to that of
TT30, which is rapidly cleared from the circulation in the
Cfh− /− model (conference report/abstract; Ruseva et al.37)
and cleared in ~ 9 h after intravenous injection into BALB/c
mice.18 Both constructs would be considered as large enough
to avoid renal filtration38 and we could not detect FH1–5^18–20
in the urine of wild-type mice injected with a 6 nmol dose at
any time point during 24 h analysis (background signal, below
limit of detection, data not shown). The clearance process
appears to be independent of the presence of glomerular C3
as FH1–5^18–20 was also rapidly lost from the serum of injected
wild-type C57BL/6 mice (Supplementary Figure S4 online). In
contrast, FH has a serum half-life of ~ 2 days when
administered to Cfh− /− mice.14 Therefore, removal of the
SCRs 6–17 appears to have reduced the expected serum half-
life by up to 50-fold. Detection of FH and FH1–5^18–20 within
the glomeruli was only visualized using a high dose of
biotinylated OX-24 antibody, which may reflect low levels or
reduced accessibility to the antigenic site of the injected
proteins, highlighting the need for detailed pharmacokinetic
analysis using directly labeled reagents. Furthermore, our
in vivo data addresses the effectiveness of FH1–5^18–20 in the
absence of endogenous FH, but the efficacy of supplementation
of normal levels of FH with FH1–5^18–20 remains to be seen.
Data from experiments in Cr2− /− mice, which demonstrate
higher complement turnover in the presence of normal FH
levels,39 suggest that increasing levels of FH1–5^18–20 can
prevent increased complement turnover (and its downstream
effects; manuscript in preparation), thereby providing some
evidence that FH functional supplementation is feasible.
In conclusion, short-term efficacy of FH1–5^18–20 in
murine experimental C3G offers the exciting prospect of an
effective treatment for C3G and other complement-mediated
renal pathologies. Despite the short serum half-life of
FH1–5^18–20, we believe these in vivo data strengthen the case
for further development and preclinical evaluation of mini-
FH therapeutics.
MATERIALS AND METHODS
Proteins and antibodies
FH, C3b, FI, factor B (FB), factor D (FD), and the goat anti-human
FH polyserum were purchased from Complement Technologies
(Tyler, TX). FH used in the in vivo studies was purified from normal
human serum, in-house, using an OX-24 column. Horse radish
peroxidase (HRP)–conjugated bovine (805-035-180-JIR) or donkey
(705-036-147-JIR) anti-goat immunoglobulin polyserum or sheep
anti-mouse immunoglobulin G (515-035-071-JIR) was purchased
from Stratech Scientific (Peterborough, UK). Human C3 for use in
the C3 convertase assay was purified from human serum using
polyethylene glycol precipitation, anion, and gel filtration chromato-
graphy as described previously.40 The L20/3 and C18/3 anti-human
FH antibodies were purchased from BioLegend (London, UK). The
FH monoclonal antibody OX-24 was purified from hybridoma
(catalog no. 00010402; Sigma, Dorset, UK) tissue culture super-
natant, in-house, by protein G chromatography. Biotinylation or
attachment of OX-24 to normal human serum–activated HiTrap
columns was carried out in strict accordance with the manufacturer’s
guidance (Lightening link, Innova Biosciences, Cambridge, UK and
GE Healthcare, Buckinghamshire, UK, respectively).
Mice
Cfh− /− mice were generated as described previously12 and
backcrossed onto the C57BL/6 genetic background. Mice used were
9–10 weeks old and sex matched. Animals were housed in the animal
facility at Imperial College, London, UK, and all experiments were
conducted in accordance with institutional guidelines and approved
by the UK Home Office. Before each experiment, all mice tested
negative for dipstick hematuria (0) and proteinuria (⩽1+) using
Hema-Combistix (Siemens, Berlin, Germany).
Construct design
The recombinant FH SCRs 1–5 expression vector was generated by
PCR amplification of SCRs 1–5 (residues 1–323) from an in-house
cloned and verified pBluescript vector containing the complete FH
cDNA (NP_000177.2) using primers to introduce a SalI restriction
site at the 3′ end and a hexa-histidine tag, stop codon, and NheI
restriction site at the 5′ end (fwd, 5′-ATAGCTGTCGACGCCACCAT
GAGACTTCTAGCAA-3′ and rev, 5′-CGCGCTAGCTTAATGATG
ATGATGATGATGTTTCAAGGTACATCTC-3′, respectively). For
recombinant FH1–5^18–20, SCRs 1–5 was amplified using the forward
primer above and a new reverse primer to introduce a hexa-histidine
tag and KpnI restriction site (5′-GAGATGTACCTTGAAACATCA
TCATCATCATCATGGTACCATCGACTG-3′). SCRs 18–20 were
then amplified with primers introducing a KpnI restriction site
at the 3′ end and a stop codon and NheI restriction site at the 5′ end
(5′-ACATATGGTACCACCTCCTGTGTGAATTCC-3′ and 5′-TGTT
ATGCTAGCTTATCTTTTTGCACAAGTTGG-3′, respectively). CFHR1
(NM-002113) and CFHR5 (NM-030787) were PCR cloned from
commercially available plasmids (IMAGE Consortium; Source
Bioscience, Nottingham, UK) with flanking XbaI/6 × His+BamHI
or SpeI/6 × His+BamHI sequences, respectively. All constructs were
cloned into the pDR2EF1α mammalian expression vector41,42 using
the appropriate restriction sites, sequence verified, and transfected
into Chinese hamster ovary cells using jetPEI (Polyplus; VWR,
Leicestershire, UK) following the standard protocols. The proteins
were batch purified using nickel-affinity chromatography according
to the manufacturer’s guidance (GE Healthcare). FH1–5^18–20 was
polished using an in-house-generated OX-24 affinity column.
Extinction coefficients (ε) and theoretical molecular weights of
recombinant (r)FHR1 (36.5 kDa, ε 65,080), rFHR5 (63.3kDa, ε
94,500), FH1–5 (35.5 kDa, ε 59,580), and FH1–5^18–20 (58.9 kDa, ε
98,720) were calculated using the ExPASy Protparam tool (Swiss
Institute of Bioinformatics, Lausanne, Switzerland).
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Ligand binding ELISAs
For C3b binding, C3b (5 μg/ml in phosphate-buffered saline (PBS))
was coated to Nunc Maxisorp (Dutscher-Scientific, Grays, UK) 96-
well plates overnight at 4 °C. Nonspecific binding was blocked with
PBS/2% bovine serum albumin (BSA) for 2 h at room temperature.
FH, FH1–5, and FH1–5^18–20 were added at 10 nmol/l in PBS/2% BSA,
and incubated for 2 h at room temperature. Preincubation of
samples with monoclonal antibodies OX-24 and L20/3 or L20/3 at
1.5 molar equivalent to FH was carried out as indicated. Goat
anti-human FH polyserum, followed by HRP–conjugated donkey
anti-goat immunoglobulin polyserum, was used for detection of the
FH proteins. TMB (3,3′,5,5′-tetramethylbenzidine) substrate was
used to develop the assay, after stopping with 10% H2SO4, and the
absorbance was read at 450 nm.
For heparin binding, the plates were coated with poly-L-lysine
(molecular weight 30–150 kDa; Sigma) at 50 μg/ml in H2O overnight
at 4 °C. After washing with PBS/0.05% Tween-20, heparin (Sigma)
was added at 25 μg/ml in H2O and then incubated for 2 h at room
temperature. After washing and blocking, the protocol was followed
as for C3b binding.
For the FHR C3b binding and competition ELISA, as per
Goicoechea de Jorge et al.,22 25 μg/ml of C3b was coated to Nunc
Maxisorp plates in a carbonate buffer with pH 9.6. Plates were
washed in PBS/0.01% Tween and incubated with PBS/2% BSA for
2 h. Equimolar concentration of FH, FH1–5, or FH1–5^18–20 were
mixed 1:1 with decreasing concentration of FHR1 or FHR5 protein
starting from 1.8 and 0.6 μmol/l, respectively, and applied to the
plate. After 2 h at room temperature, plates were washed 4 × and
then incubated with a 2 μg/ml OX-24. After 1 h, plates were washed
again and incubated with a 1/1000 dilution of sheep anti-mouse
immunoglobulinG-HRP. Plates were washed 4 × and developed
as above.
SRBC–based hemolytic assays
(a) The FH loss-of-function assay was undertaken essentially as
previously described by Sanchez-Corral et al.25 using normal human
serum (negative control) and serum from an affected aHUS patient
known to carry the CFH/CFHR1 hybrid gene (positive control;
Venables et al.43). Normal human serum was also premixed with
increasing quantity of OX-24 (1.2 mg/ml in AP buffer) as needed.
See Supplementary Methods online for full details.
(b) Decay acceleration on sheep erythrocytes: C3b-coated sheep
erythrocytes were prepared as described previously.24 Cells were
resuspended to 2% (vol/vol) in AP buffer. The AP convertase was
formed on the cell surface by incubating 50 μl cells with 50 μl of
AP buffer containing FB (3 μg/ml) and FD (0.2 μg/ml) at 37 °C for
15 min. The cells (100 μl) were then added to 50 μl of either FH
(0.4–50 nmol/l), FH1–5^18–20 (0.4–50 nmol/l), or FH1–5 (3–400 nmol/l)
in PBS/20mmol/l ethylenediaminetetraacetic acid (EDTA) and
incubated at 25 °C for 15min. Lysis was developed by adding 50 μl
of 4% (vol/vol) normal human serum depleted of FB and FH24 in
PBS/20mM EDTA and incubating at 37 °C for 25min. To determine
the amount of lysis, cells were pelleted by centrifugation, and
hemoglobin release was measured at 420 nm (A420). The percentage
of inhibition from lysis was calculated by the formula (A420 (buffer
only)−A420 (FH))/A420 (buffer only) × 100%. Controls included 0%
lysis (buffer only—PBS/20mM EDTA) and 100% lysis (0.01% Triton
in PBS/20mM EDTA).
(c) Measuring FH cofactor activity: C3b-coated sheep erythrocytes
were resuspended to 2% (vol/vol) in AP buffer. Fifty microliters of
cells was added to an equal volume of AP buffer containing 2.5 μg/ml
FI and either FH (0.8–100 nmol/l), FH1–5^18–20 (0.8–100 nmol/l), or
FH1–5 (6–750 nmol/l) and incubated at 25 °C for 8 min. After three
washes in AP buffer, cells were resuspended in 50 μl of AP buffer. A
further 50 μl of AP buffer containing FB (4 μg/ml) and FD (0.4 μg/
ml) was added to cells and incubated at 25 °C for 15 min to form AP
convertase on the remaining erythrocyte surface-bound C3b. Lysis
was developed by adding 50 μl 4% (vol/vol) normal human serum
depleted of FB and FH in PBS/20 mM EDTA and incubating at 37 °C
for 20 min. Percentage inhibition of lysis was calculated as in
part (b).
Administration of serum-derived FH, FH1–5^18–20, and FH1–5 to
Cfh− /− mice
All materials administered to animals were subjected to lipopoly-
saccharide removal,44 and were confirmed to be lipopolysaccharide
free by the method of Moesby et al.45 Based on the FH dose used
successfully in Fakhouri et al.,14 mice were injected intraperitoneally
with serum-derived full-length human FH (3 nmol/465 μg per
animal), FH1–5^18–20 (12 nmol/710 μg), or FH1–5 (12 nmol/424 μg)
in identical volumes of PBS, or PBS alone. Blood was collected onto
EDTA via tail venesection before injection and at serial time points
thereafter, with plasma separated via centrifugation for storage at
− 80 °C. Mice were killed at the indicated time points, and the
kidneys were collected into PBS and snap frozen in OCT embedding
matrix (CellPath, Newtown, UK) for storage at − 80 °C.
Measurement of mouse plasma C3 or FH reagents by ELISA
Mouse C3 levels were measured by ELISA using HRP–conjugated
goat polyclonal anti-mouse C3 Ab (MP Biomedicals, Santa Ana, CA;
catalog no. 0855557) as described previously.12 Alternatively, to
detect human FH or our constructs, OX-24 (5 μg/ml) was used as
capture and goat anti-human FH, followed by bovine anti-goat-HRP
used as detection in standard ELISA (see Supplementary Methods
online).
Immunostaining of mouse renal sections for murine C3 and
C3d, and human FH
Five micrometer cryosections from mouse kidneys were mounted on
SuperFrost glass slides (VWR, Lutterworth, UK) coated with 0.1%
(v/v) poly-L-lysine in H2O (Sigma), before fixing in acetone and
storage at − 80 °C. Thirty-minute blocking and 1 h staining steps
were performed at room temperature, with 60 μl applied per thawed
section. For mouse C3, blocking was with 20% (v/v) goat serum
(Sigma) in PBS, and detection was with 1 in 200 FITC–conjugated
goat polyclonal anti-mouse C3 Ab (MP Biomedicals; catalog no.
0855500; 4 mg/ml) in PBS. For mouse C3d, blocking was with 2%
BSA/PBS, followed by the Biotin Blocking System (Dako, Glostrup,
Denmark), and detection was with 1 in 10 biotinylated polyclonal
goat anti-mouse C3d Ab (R&D Systems, Abingdon, UK; catalog no.
BAF2655; 50 mg/ml) in 2% BSA/PBS, followed by rinsing and
secondary detection with 1 in 400 phycoerythrin-conjugated
streptavidin (BD Pharmingen, Oxford, UK; catalogue no. 554061;
0.5 mg/ml) in PBS. For human FH, blocking was with the Biotin
Blocking System and detection was with 1 in 25 biotinylated Ox-24
(1 mg/ml) in PBS, followed by rinsing and secondary detection using
1 in 400 phycoerythrin-conjugated streptavidin (BD Pharmingen;
catalogue no. 554061; 0.5 mg/ml) in PBS. After rinsing, slides were
mounted in VECTASHIELD HardSet Mounting Medium with DAPI
(4',6-diamidino-2-phenylindole; Vector Laboratories, Burlingame,
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CA) and covered with glass coverslips. Sections were visualized at
original magnification × 40 using an Olympus BX40 microscope with
a BX-FLA vertical fluorescence illuminator (Olympus, Tokyo,
Japan). Ten glomeruli per section were identified based on
glomerular clusters of DAPI–positive cells. Immunofluorescence
images were then captured and quantitative immunofluorescence
was performed using a QImaging Retiga 2000R digital camera
(QImaging, Surrey, BC, Canada) and Image-Pro Plus 7.0 software
(Media Cybernetics, Warrendale, PA). Mean fluorescence intensity
for each section is expressed in arbitrary fluorescence units.
Statistical analysis
Data were analyzed using GraphPad Prism 6.00 for Windows
(GraphPad Software, San Diego, CA; www.graphpad.com). Groups
were compared at each time point using one- or two-way analysis of
variance with Bonferroni multiple comparisons test as indicated.
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SUPPLEMENTARY MATERIAL
Figure S1. (A) FH1-5 mediated accelerated decay of the AP C3
convertase was measured by surface Plasmon resonance essentially
as described in Schmidt et al, 2011.
Figure S2. (A) Fluid-phase FI cofactor activity of FH1-5^18-20 was
measured by incubation of C3b and FI with for 30 min at 37°C.
Figure S3. Effect of repeat administration of FH1-5^18-20 on glomerular
staining of 8 week old, sex matched, FH-/- mice over 24 hours.
Figure S4. Six C57Bl/6 (wild type) mice were injected I.P. with a 3nmol
dose of FH1-5^18-20 while two mice received only PBS as control.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Whaley K, Ruddy S. Modulation of the alternative complement pathways
by beta 1 H globulin. J Exp Med 1976; 144: 1147–1163.
2. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement
factor H. Biochemistry 2013; 52: 3949–3962.
3. Weiler JM, Daha MR, Austen KF et al. Control of the amplification
convertase of complement by the plasma protein beta1H. Proc Natl Acad
Sci USA 1976; 73: 3268–3272.
4. Langford-Smith A, Keenan TD, Clark SJ et al. The role of complement in
age-related macular degeneration: heparan sulphate, a ZIP code for
complement factor H? J Innate Immun 2014; 6: 407–416.
5. Clark SJ, Ridge LA, Herbert AP et al. Tissue-specific host recognition by
complement factor H is mediated by differential activities of its
glycosaminoglycan-binding regions. J Immunol 2013; 190: 2049–2057.
6. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E et al.
The human complement factor H: functional roles, genetic variations and
disease associations. Mol Immunol 2004; 41: 355–367.
7. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy:
consensus report. Kidney Int 2013; 84: 1079–1089.
8. Servais A, Noel LH, Roumenina LT et al. Acquired and genetic complement
abnormalities play a critical role in dense deposit disease and other C3
glomerulopathies. Kidney Int 2012; 82: 454–464.
9. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit
disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7:
748–756.
10. Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy.
Nephrol Dial Transplant 2014.
11. Le Quintrec M, Lionet A, Kandel C et al. Eculizumab for treatment of
rapidly progressive c3 glomerulopathy. Am J Kidney Dis 2015; 65:
484–489.
12. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes
membranoproliferative glomerulonephritis in mice deficient in
complement factor H. Nat Genet 2002; 31: 424–428.
13. Paixao-Cavalcante D, Hanson S, Botto M et al. Factor H facilitates the
clearance of GBM bound iC3b by controlling C3 activation in fluid phase.
Mol Immunol 2009; 46: 1942–1950.
14. Fakhouri F, de Jorge EG, Brune F et al. Treatment with human
complement factor H rapidly reverses renal complement deposition in
factor H-deficient mice. Kidney Int 2010; 78: 279–286.
15. Sharma AK, Pangburn MK. Biologically active recombinant human
complement factor H: synthesis and secretion by the baculovirus system.
Gene 1994; 143: 301–302.
16. Sanchez-Corral P, Perez-Caballero D, Huarte O et al. Structural and
functional characterization of factor H mutations associated with atypical
hemolytic uremic syndrome. Am J Hum Genet 2002; 71: 1285–1295.
17. Buttner-Mainik A, Parsons J, Jerome H et al. Production of biologically
active recombinant human factor H in Physcomitrella. Plant Biotechnol J
2011; 9: 373–383.
18. Huang Y, Qiao F, Atkinson C et al. A novel targeted inhibitor of the
alternative pathway of complement and its therapeutic application in
ischemia/reperfusion injury. J Immunol 2008; 181: 8068–8076.
19. Cheng ZZ, Hellwage J, Seeberger H et al. Comparison of surface
recognition and C3b binding properties of mouse and human
complement factor H. Mol Immunol 2006; 43: 972–979.
20. Gordon DL, Kaufman RM, Blackmore TK et al. Identification of complement
regulatory domains in human factor H. J Immunol 1995; 155: 348–356.
21. Jokiranta TS, Zipfel PF, Hakulinen J et al. Analysis of the recognition
mechanism of the alternative pathway of complement by monoclonal
anti-factor H antibodies: evidence for multiple interactions between H
and surface bound C3b. FEBS Lett 1996; 393: 297–302.
22. Goicoechea de Jorge E, Caesar JJ, Malik TH et al. Dimerization of
complement factor H-related proteins modulates complement activation
in vivo. Proc Natl Acad Sci USA 2013; 110: 4685–4690.
23. Pechtl IC, Kavanagh D, McIntosh N et al. Disease-associated N-terminal
complement factor H mutations perturb cofactor and decay-accelerating
activities. J Biol Chem 2011; 286: 11082–11090.
24. Tortajada A, Montes T, Martinez-Barricarte R et al. The disease-protective
complement factor H allotypic variant Ile62 shows increased binding
affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009; 18:
3452–3461.
25. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S et al.
Functional analysis in serum from atypical hemolytic uremic syndrome
patients reveals impaired protection of host cells associated with
mutations in factor H. Mol Immunol 2004; 41: 81–84.
26. Francis NJ, McNicholas B, Awan A et al. A novel hybrid CFH/CFHR3 gene
generated by a microhomology-mediated deletion in familial atypical
hemolytic uremic syndrome. Blood 2012; 119: 591–601.
27. Sim E, Palmer MS, Puklavec M et al. Monoclonal antibodies against the
complement control protein factor H (beta 1 H). Biosci Rep 1983; 3: 1119–1131.
28. Fenaille F, Le Mignon M, Groseil C et al. Site-specific N-glycan
characterization of human complement factor H. Glycobiology 2007; 17:
932–944.
29. Schmidt CQ, Slingsby FC, Richards A et al. Production of biologically active
complement factor H in therapeutically useful quantities. Protein Expr Purif
2011; 76: 254–263.
30. Li H, d'Anjou M. Pharmacological significance of glycosylation in
therapeutic proteins. Curr Opin Biotechnol 2009; 20: 678–684.
31. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of
pathogens-acquisition of inhibitors and beyond. Mol Immunol 2009; 46:
2808–2817.
32. Schneider MC, Prosser BE, Caesar JJ et al. Neisseria meningitidis recruits
factor H using protein mimicry of host carbohydrates. Nature 2009; 458:
890–893.
8 Kidney International
bas i c resea rch E-M Nichols et al.: Mini-FH ameliorates C3G
33. Shaughnessy J, Lewis LA, Jarva H et al. Functional comparison of the
binding of factor H short consensus repeat 6 (SCR 6) to factor H binding
protein from Neisseria meningitidis and the binding of factor H SCR 18 to
20 to Neisseria gonorrhoeae porin. Infect Immun 2009; 77: 2094–2103.
34. Blanc C, Togarsimalemath SK, Chauvet S et al. Anti-Factor H
autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic
syndrome: one target, two diseases. J Immunol 2015; 194: 5129–5138.
35. Hebecker M, Alba-Dominguez M, Roumenina LT et al. An engineered
construct combining complement regulatory and surface-recognition
domains represents a minimal-size functional factor H. J Immunol 2013;
191: 912–921.
36. Schmidt CQ, Bai H, Lin Z et al. Rational engineering of a minimized
immune inhibitor with unique triple-targeting properties. J Immunol 2013;
190: 5712–5721.
37. Ruseva MM, Peng T, Wang Y et al. Efficacy of targeted complement
inhibition in experimental C3 glomerulopathy. In: Tambourgi DV,
Fishelson Z (eds). XXV International Complement Workshop, Vol. 61.
Elsevier: Rio de Janeiro, Brazil, 2014, p 256.
38. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier
and mechanisms of proteinuria. Physiol Rev 2008; 88: 451–487.
39. Jacobson AC, Weis JJ, Weis JH. Complement receptors 1 and 2 influence
the immune environment in a B cell receptor-independent manner.
J Immunol 2008; 180: 5057–5066.
40. Harris CL. Functional assays for complement regulators. Methods Mol Biol
2000; 150: 83–101.
41. Charreau B, Cassard A, Tesson L et al. Protection of rat endothelial cells
from primate complement-mediated lysis by expression of human CD59
and/or decay-accelerating factor. Transplantation 1994; 58: 1222–1229.
42. Yanagawa B, Spiller OB, Choy J et al. Coxsackievirus B3-associated
myocardial pathology and viral load reduced by recombinant soluble
human decay-accelerating factor in mice. Lab Invest 2003; 83: 75–85.
43. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic
syndrome associated with a hybrid complement gene. PLoS Med 2006;
3: e431.
44. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by
phase separation using Triton X-114. J Immunol Methods 1990; 132:
191–195.
45. Moesby L, Jensen S, Hansen EW et al. A comparative study of mono Mac 6
cells, isolated mononuclear cells and Limulus amoebocyte lysate assay in
pyrogen testing. Int J Pharm 1999; 191: 141–149.
This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0
International License. The images or other third party
material in this article are included in the article’s Creative
Commons license, unless indicated otherwise in the credit
line; if the material is not included under the Creative
Commons license, users will need to obtain permission from
the license holder to reproduce thematerial. To view a copy of
this license, visit http://creativecommons.org/licenses/by-nc-
sa/4.0/
Kidney International 9
E-M Nichols et al.: Mini-FH ameliorates C3G bas i c resea rch
